Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy…
<!-- Name:DistributionId Value:8741270 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
wet AMD
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study…
<!-- Name:DistributionId Value:8741606 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Graybug Vision Reports Financial Results for the Three and Nine Months Ended…
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically…
Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight
New York, USA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight DelveInsight’s Wet AMD pipeline analysis depicts…
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX…
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a…
Graybug to Present at the 2022 OIS Retina Innovation Summit
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the…
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical…
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the…
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the…
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for…
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a…
ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore…